AIHealthcare

Variational AI is a Vancouver, Canada-based, venture-backed generative-AI drug-discovery company. Its proprietary Enki™ platform is a foundation-model-based system for designing and optimizing novel, selective, synthesizable small-molecule lead candidates, with the stated aim of accelerating and de-risking early-stage discovery. The company works through biopharma partnerships and has described development of an internal pipeline; reported collaborations include Merck Research Laboratories, including a January 2024 early-access Enki project supported by CQDM’s Quantum Leap program and a September 2025 collaboration covering two undisclosed targets. The company positions itself in the generative-AI small-molecule discovery market rather than as a clinical-stage therapeutics developer.